These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25363231)

  • 1. NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma.
    Varga G; Mikala G; Andrikovics H; Koszarska M; Balassa K; Ádám E; Kozma A; Tordai A; Masszi T
    Br J Haematol; 2015 Mar; 168(5):679-88. PubMed ID: 25363231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
    Vangsted AJ; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Nexø BA; Vogel U
    Ann Hematol; 2011 Oct; 90(10):1173-81. PubMed ID: 21347685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support.
    Vangsted AJ; Klausen TW; Gimsing P; Andersen NF; Abildgaard N; Gregersen H; Vogel U
    Haematologica; 2009 Sep; 94(9):1274-81. PubMed ID: 19734419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association of a functional -94ins/delATTG NFKB1 promoter polymorphism with susceptibility and clinical expression of biopsy-proven giant cell arteritis in northwest Spain.
    Martin J; Perez-Armengol C; Miranda-Filloy JA; Vilchez JR; Lopez-Nevot MA; Garcia-Porrua C; Gonzalez-Gay MA
    J Rheumatol; 2006 Feb; 33(2):285-8. PubMed ID: 16465659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional polymorphism of the NFKB1 gene promoter is not relevant in predisposition to celiac disease.
    Rueda B; Núñez C; López-Nevot MA; Paz Ruiz M; Urcelay E; De la Concha EG; Martín J
    Scand J Gastroenterol; 2006 Apr; 41(4):420-3. PubMed ID: 16635909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
    Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NFKB1 promoter -94 insertion/deletion ATTG polymorphism (rs28362491) is associated with severity and disease progression of rheumatoid arthritis through interleukin-6 levels modulation in Egyptian patients.
    Elkhawaga SY; Gomaa MH; Elsayed MM; Ebeed AA
    Clin Rheumatol; 2021 Jul; 40(7):2927-2937. PubMed ID: 33459954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia.
    Riemann K; Becker L; Struwe H; Nückel H; Dührsen U; Alakus H; Winde G; Neuhäuser M; Rübben H; Schmitz KJ; Wohlschlaeger J; Schmid KW; Siffert W
    Pharmacogenet Genomics; 2006 Nov; 16(11):783-8. PubMed ID: 17047486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
    Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
    J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of NFKB1 -94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: a meta-analysis.
    Zou YF; Wang F; Feng XL; Tao JH; Zhu JM; Pan FM; Su H
    Tissue Antigens; 2011 Jan; 77(1):9-17. PubMed ID: 21155719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NFKB1 promoter polymorphism (-94ins/delATTG) alters nuclear translocation of NF-κB1 in monocytes after lipopolysaccharide stimulation and is associated with increased mortality in sepsis.
    Adamzik M; Schäfer S; Frey UH; Becker A; Kreuzer M; Winning S; Frede S; Steinmann J; Fandrey J; Zacharowski K; Siffert W; Peters J; Hartmann M
    Anesthesiology; 2013 Jan; 118(1):123-33. PubMed ID: 23249930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
    Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
    Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NFKB1 -94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors.
    Burnik FS; Yalçin S
    Chemotherapy; 2009; 55(5):381-5. PubMed ID: 19752553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.
    Du J; Huo J; Shi J; Yuan Z; Zhang C; Fu W; Jiang H; Yi Q; Hou J
    Haematologica; 2011 May; 96(5):729-37. PubMed ID: 21228035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the functional NFKB1 promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus.
    Orozco G; Sánchez E; Collado MD; López-Nevot MA; Paco L; García A; Jiménez-Alonso J; Martín J
    Tissue Antigens; 2005 Feb; 65(2):183-6. PubMed ID: 15713218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between obesity and the NFKB1 - 94ins/delATTG promoter polymorphism in relation to incident acute coronary syndrome: a follow up study in three independent cohorts.
    Stegger JG; Schmidt EB; Berentzen TL; Tjønneland A; Vogel U; Rimm E; Sørensen TI; Overvad K; Jensen MK
    PLoS One; 2013; 8(5):e63004. PubMed ID: 23671649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
    Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma.
    Qin Y; Lu J; Bao L; Zhu H; Li J; Li L; Lai Y; Shi H; Wang Y; Liu Y; Jiang B; Huang X
    Chin Med J (Engl); 2014; 127(9):1666-71. PubMed ID: 24791872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
    White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
    Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.